The results of a large, international systematic review published in the journal PLOS Medicine show that tuberculosis treatment is successful in children with multidrug-resistant tuberculosis (MDR-TB). The study was used to inform the World Health Organization guidelines on treatment of MDR-TB in children.
At a time when drug overdoses are becoming more prevalent and lethal, a new report provides a snapshot of regional illicit drug use and, for the first time, highlights the complexity of detecting and treating patients at hospital emergency departments for a severe drug-related event.
The number of cases of progressive massive fibrosis (PMF) among US coal miners has risen during the past two decades, even as the number of coal miners has declined, according to new research published online in the Annals of the American Thoracic Society.
Researchers have found that cholesterol-lowering statins may improve the conditions of people with a rare lung disease called autoimmune pulmonary alveolar proteinosis. The research also suggested that two new tests could help diagnose the condition.
A team of researchers from Penn Medicine has developed the first mouse model with an IPF-associated mutation, which induces scarring and other damage similar to what is observed in humans suffering from the condition.
Autoimmunity plays a role in the development of chronic obstructive pulmonary disease (COPD), according to a study led by Georgia State University and Vanderbilt University Medical Center that analyzed human genome information stored in Vanderbilt's DNA biobank.
Muscles of the elderly and of patients with Duchene muscular dystrophy have trouble regenerating. A new nanohydrogel with muscle stem cells has boosted muscle growth in mouse models while protecting the stem cells from immune reactions that usually weaken or destroy them.
Phase I results of olaparib with cetuximab and radiation led to 72 percent 2-year survival in 16 patients on trial, compared with an expected 2-year survival rate of about 55 percent for standard-of-care treatment.
New research published in Cell Reports from scientists at the National Institute of Allergy and Infectious Diseases (NIAID) shows how MERS-CoV can adapt to infect cells of a new species, which suggests that other coronaviruses might be able to do the same.
Idiopathic pulmonary fibrosis (IPF) is an incurable lung disease of unknown origin with limited treatment options. Research suggests that the signaling molecule WNT5A plays a key role in the pathogenic process. Now a group of scientists from Helmholtz Zentrum München working with colleagues from the University of Denver have taken a further step towards uncovering the mechanisms responsible for the development of fibrosis.